Abstract | Studies performed in the liver in the 1960s led to the identification of lysosomes and the discovery of autophagy, the process by which intracellular proteins and organelles are degraded in lysosomes. Early studies in hepatocytes also uncovered how nutritional status regulates autophagy and how various circulating hormones modulate the activity of this catabolic process in the liver. The intensive characterization of hepatic autophagy over the years has revealed that lysosome-mediated degradation is important not only for maintaining liver homeostasis in normal physiological conditions, but also for an adequate response of this organ to stressors such as proteotoxicity, metabolic dysregulation, infection and carcinogenesis. Autophagic malfunction has also been implicated in the pathogenesis of common liver diseases, suggesting that chemical manipulation of this process might hold potential therapeutic value. In this Review-intended as an introduction to the topic of hepatic autophagy for clinical scientists-we describe the different types of hepatic autophagy, their role in maintaining homeostasis in a healthy liver and the contribution of autophagic malfunction to liver disease.
Introduction
Autophagy is the term (from the Greek words 'auto' meaning 'self ' and 'phagy' meaning 'to eat') adopted to describe the series of molecular reactions that ultimately result in the degradation of intracellular components in lysosomes.
1,2 Breakdown of proteins and organelles and the subsequent recycling of their essential constituents occur in all types of cells and organs with different pur poses. It is intuitive to infer that degradation is an ef ficient method of cellular 'cleaning' . Proteins and organelles bearing any type of abnormality due to faulty synthesis, or that become damaged by intracellular or extracel lular stressors, need to be removed before they become toxic. 3 In this respect, autophagy is one of the most power ful systems for cellular cleanup, as lysosomal hydro lases can degrade all type of macromolecules (protein, lipids, nucleic acids and complex sugars). 4 However, the functions of autophagy go far beyond the elimination of damaged cellular components and protein quality control. In fact, all intracellular proteins and organelles, even if they are not damaged, undergo some degree of continuous synthesis and degradation. This recycling allows for their renewal and prevents malfunction due to wear and tear. 3 An additional reason for degradation of macro molecular structures is to utilize their breakdown products as an internally derived source of energy. 5, 6 Autophagic degradation of macromolecular structures in lysosomes generates amino acids, free fatty acids and carbohydrate moieties that can be recycled for synthesis of new cellular components or further oxidized to gener ate ATP, mostly in conditions when nutrients are scarce. Both degradation and recycling are particularly impor tant in highly metabolically active organs such as the liver, in which periods of starvation as short as 4 h are enough to induce maximal activation of autophagy. 7 Interestingly, this starvationinduced upregulation of autophagy in the liver led to the initial identifica tion of this pathway in mammals. 7 Early studies (in the 1960s and 1970s) in hepatocytes also provided detailed descriptions of the vesicles that participate in the seques tration and delivery of cytosolic material to lysosomes. Quantification of the changes in the number and size of these vesicles and in liver protein turnover led to the characterization of the regulatory effect of select amino acids and hormones, such as insulin and glucagon, on hepatic autophagy. [7] [8] [9] However, identification of the genes responsible for autophagy did not begin until 30 years later, when a detailed molecular dissection of this process was performed in yeast. 10 Discovery of the genes control ling autophagy and the fact that most of them are con served from yeast to mammals 11 has provided momentum for numerous studies connecting malfunctioning of the autophagic system with different human diseases such as cancer, neurodegeneration, myopathies, infectious con ditions and metabolic disorders. 1, 2 Modulating autophagy for therapeutic purposes holds potential for the treatment of the plethora of disease states in which autophagic pro cesses are dysregulated. In fact, pharmacological manip ulation of autophagy has already begun testing in clinical trials for different types of cancers and for some severe neuronal and muscular degenerative diseases.
The liver, the organ in which autophagy research started, has also benefited from this enhanced under standing of autophagy, a process that is tightly connected to hepatic pathophysiology. This Review is intended as an introduction for clinical scientists to the topic of hepatic autophagy, its contribution to liver physiology and to the growing number of liver diseases linked to autophagic malfunction.
Autophagic pathways in the liver
Hepatocytes, like most cells, have many ways to trans port cytosolic material (cargo) to lysosomes for degrad ation. The identification of the mechanisms behind these Key points ■ Autophagy contributes to the maintenance of the energetic balance, participates in hepatocyte quality control and aids in the defence against exogenous pathogens and conditions that cause cellular toxicity in the liver ■ The different autophagic pathways that coexist in the liver are in dynamic intercommunication with one another, enabling a coordinated response to maintain homeostasis ■ Failure to properly execute the autophagic program leaves hepatocytes vulnerable to stressors and unable to accommodate the extreme energetic demands of this organ ■ Autophagy malfunction underlies the pathogenesis of common liver diseases, including metabolic disorders, protein conformational diseases, viral infection and carcinogenesis ■ Chemical modulation of autophagy has proven to be beneficial in certain liver pathologies, although manipulation of autophagy needs to be customized according to the status of the autophagic pathway in each disease state different methods of delivery has helped define three coexisting types of autophagy: macroautophagy, micro autophagy and chaperonemediated autophagy (CMA) ( Figure 1 ). In many of these pathways, the autophagic process can be 'constitutive' (continuously active) or 'inducible' (activated in response to stimuli). In addition, cargo can be delivered to lysosomes in bulk (through random sequestration) or selectively (by i ndividual t argeting of each cargo molecule).
Macroautophagy
The distinctive step of macroautophagy is the form ation of a doublemembraned vesicle (autophagosome), which sequesters cytosolic material to be degraded by lyso somal hydrolases once the autophagosome fuses with lyso somes (Figure 2 ). Examples of types of macro autophagy that target specific organelles for d egradation are mitophagy (mitochondria), pexophagy (peroxisomes) and lipophagy (lipid droplets). About 30 autophagy related genes and their protein products (Atgs) organize into functional complexes that act coordinately at dif ferent steps of this process (reviewed elsewhere 2, 12 ). The temporal and spatial organization of the Atg complexes initiates autophagosome form ation from sites such as the endoplasmic reticulum (ER), mitochondria, Golgi or the plasma membrane or endocytic system. Targeted autophagic degradation is possible owing to a subset of autophagy receptors, which link Atg proteins that initi ate autophagosome formation to the surface of the desig nated cargo. 13 For example, these receptors permit the identification and removal of one damaged mitochon drion from a whole pool of functional m itochondria.
14 Atg proteins also mediate the sealing of the autophago some limiting membrane, known as the phago phore or isolation membrane, that encloses the cargo; and Atg proteins also participate in the m icrotubuledependen t trafficking of the autophagosome and the ultimate fusion between autophagosomes and lyso somes. 1, 2 In certain conditions, autophago somes might instead fuse with endosomes to create an intermediary compartment (amphisome) that then delivers cargo to lysosomes. 15 The final step in macroautophagy, shared with the other autophagic pathways, is the degradation and recycling of breakdown products back into the cytosol. Several lyso somal membrane permeases involved in this recycling pathway have already been characterized in yeast, but the identification of mammalian homologues has just begun. 16 The material freed from the lysosomes (amino acids, sugars and fatty acids) is sensed by regulatory com plexes that modulate autophagy activity. For example, the mammalian target of rapamycin (mTOR), the best characterized negative regulator of macroautophagy, sits on the surface of lyso somes and is controlled by the efflux of select amino acids and glucose released from these compartments. 17 Macroautophagy was originally thought to be activated only in response to stress, such as starvation. However, macroautophagy also has a role in the unstressed liver: genetic blockage of this pathway in hepatocytes leads to accumulation of damaged organelles and altered Figure 1 | Autophagic pathways in the liver. Three different types of autophagy coexist in the liver. In macroautophagy, proteins, organelles and cytosolic material are sequestered in a double-membraned vesicle (autophagosome) to be degraded by lysosomal hydrolases once the autophagosome fuses with lysosomes. In endosomal microautophagy, small vesicles form on the surface of late endosomes and are pinched off into the lumen to be degraded. Late endosomes can sequester cargo 'in bulk' or selectively through a chaperone-cargo protein interaction. By contrast, in chaperone-mediated autophagy the substrate proteins cross the lysosomal membrane through a translocation complex instead of being delivered by vesicles. This type of transport requires the coordinated action of chaperones on the cytosolic side of the membrane that facilitate the unfolding of the substrate protein, as well as chaperones on the luminal side of the membrane that pull substrate proteins through the translocation complex one by one. 
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proteins even under basal conditions. 18 Therefore, maintenance of hepatocyte homeostasis and protein quality control requires constitutive macroautophagy. Constitutive and inducible macroautophagy share the same core Atg machinery but they are regulated dif ferently. For instance, constitutive macroautophagy is insensitive to the wellcharacterized inhibitory effects that mTOR, insulin signalling and select amino acids exert on starvationinduced macroautophagy. 19 In most organs, different stimuli (ER stress, hypoxia, oxidative stress, DNA damage or mitochondria dysfunction) can activate macroautophagy through a broad array of sig nalling pathways that include JNK (cJun Nterminal kinase), CaMKK (calcium/calmodulindependent protein kinase kinase), LKB (liver kinase B), AKT (also known as protein kinase B), Sirt1 (sirtuin 1), PERK (protein kinase RNAlike endoplasmic reticulum kinase), PDGF (plateletderived growth factor), AMPK (AMP activated protein kinase) and p53mediated signalling (reviewed elsewhere 20 ).
Microautophagy
Microautophagy was also originally described in hepatocytes as the internalization of cytosolic mat erial in lyso somes by invaginations in the lysosomal membrane ( Figure 1) . 4, 21 These invaginations pinch off from the membrane as singlemembraned vesi cles, which then undergo degradation in the lysosomal lumen. In contrast to the high conservation of the genes involved in macroautophagy, yeast microautophagy genes are not conserved in mammals. 22 Although this lack of conservation has called into question whether micro autophagy occurs in mammals, studies support the idea that a m icroautophagylike process takes place at late endosomes in mammalian cells, including hepato cytes. 23 Endosomal microautophagy utilizes components of the ESCRT (endosomal sorting complexes required for transport) complex, which is known to participate in internalization and recycling of plasma membrane proteins through formation of these endosomal vesi cles. 24 Interestingly, ESCRT proteins and functional multivesicular bodies are also required to sustain macro autophagic activity. 25 Both an in bulk and a selective form of this process mediated by the chaperone hsc70 have been described. 23 Chaperone-mediated autophagy The distinctive feature of CMA is that substrate pro teins are recognized in the cytosol by a chaperone 26 that brings them to lysosomes where they cross the mem brane through a translocation complex instead of being delivered by vesicles (Figure 1) . 27 This type of trans port requires the unfolding of the substrate protein so it can cross the lysosomal lipid bilayer and the presence of chaperones on both sides of the membrane to pull substrate proteins through one by one. The lysosome associated membrane protein type 2A (LAMP2A) 28 and the constitutively expressed chaperone hsc70, are essential players in this type of autophagy. [29] [30] [31] CMA was initially identified in fibroblasts in culture but most of its molecular character ization has been performed in the liver. Upregulation of CMA occurs as part of the cellular response to various insults such as longterm nutrient deprivation, oxidative stress and proteotoxicity. 32, 33 Autophagy in the healthy liver
The number of cellular functions known to be linked to the autophagic process has considerably expanded in the past decade as a result of the many studies using genetic and chemical approaches to block or upregulate autophagy ( Figure 3) . Comparison of transgenic mouse models with blockage of autophagy in different organs has permitted the identification of a subset of func tions of autophagy shared by all cells, as well as organ specific functions. In this section we describe two of the main f unctions at tributed to autophagy in the healthy liver.
Cellular energetic balance
Autophagy helps maintain a positive energetic balance in the liver through different mechanisms: first, through breakdown of intracellular stores of macromolecules that can be utilized for cellular fuel; second, through control of key regulatory enzymes of cellular metab olism; and third, through preservation of mitochondrial h omeostasis by efficient organelle turnover. 
Breakdown of intracellular energy stores
Hepatic macroautophagy is rapidly activated during the first 4-6 h of starvation. This increase in protein degrad ation replenishes the pool of intracellular amino acids and thus preserves protein synthesis under these con ditions. 21 The amino acids from the lysosomal break down can also enter the Krebs cycle and contribute to ATP generation [34] [35] [36] or be utilized for gluconeogenesis. 37 This autophagymediated adaptation to starvation is essential in neonates during the critical period between interruption of the transplacental supply of nutrients and lact ation. In fact, mice lacking essential autophagy genes, although normal at birth, die in the first days of life owing to their inability to sustain high enough concentrations of amino acids to maintain ATP levels and the synthesis of essential proteins. 38 Moreover, mice with specific deletion of essential autophagy genes in the liver have a marked inability to adapt to nutrient deprivation owing to failure of starvationinduced proteolysis and lipolysis. 18 The energetic imbalance in these mice is further aggravated by the fact that mitochondria function, which is essential for betaoxidation of lipids, is compromised due to the inefficient turnover of these organelles by autophagy. 18 Activation of liver macroautophagy during starvation is promoted by the increase in circulating glucagon and the concomitant decrease in circulating levels of insulin and amino acids, which are both potent inhibitors of hepatic macroautophagy. 7, 9 Degradation of proteins by macro autophagy in the liver declines by 8 h into the starvation period and is followed by a gradual activation of CMA. 39 Hepatic CMA activity reaches its maximum at 24 h after nutrient deprivation and remains activated for up to 3 days, serving as an internal source of amino acids. 39 The mechanisms that trigger this activation of CMA in response to starvation are for the most part unknown. Signalling through the retinoic acid receptor α (RARα) is the only pathway described so far that modulates CMA activity. 40 However, this pathway might not have an important role in the activation of CMA during starvation because the inhibition of CMA by retinoic acid signalling is insensitive to nutritional changes, and antagonists of RARα have an additive effect with star vation on CMA activation. 40 Early studies analysed the possible stimu latory role of ketone bodies on CMA because ketones are generated in the liver during prolonged starvation. 41 Although increased rates of CMA can be observed upon exposure of cultured cells to ketone bodies, these mol ecules do not mediate signalling but rather induce oxida tion of proteins, which explains the increase in selective degradation through CMA. 41 Given that activation of CMA by starvation does not require protein trans lation or synthesis, and that the increase in the lysosomal levels of the receptor for this pathway during starvation is mainly the result of a decrease in the lysosomal turn over of this receptor, 42 it is likely that starvationmediate d changes directly in the lysosomal compartment are responsible for CMA activation. In this respect, it would be interesting to elucidate if, as in the case of macro autophagy, nutrientsensing proteins at the lysosomal membrane are responsible for modulating the levels and organization of the CMA translocation complex.
Macroautophagy also persists in the liver after 8 h of starvation but there is a shift in the type of cargo seques tered by autophagosomes from proteins to lipids. 43 Lipid droplets-cytosolic stores of triglycerides and cholesterol esters-are trapped inside autophagosomes and deliv ered to lysosomes for breakdown by the resident lyso somal lipases through a selective form of macro autophagy named macrolipophagy. [43] [44] [45] Lysosomemediated lipo lysis is independent from the lipolytic process carried out by the cytosolic lipases and depends instead on intra lysosomal lipases. 46, 47 Studies have shown that a whole transcriptional programme is activated in the liver during starvation to prepare the autophagic/lysosomal system (including organelles and their enzymatic content) for the arrival and processing of the lipid cargo. 47, 48 Although the relative contribution of lysosomal lipophagy to overall lipolysis under normal conditions might be discrete, lipophagy prevents massive accumulation of hepatic lipids in response to dietary lipid overload. [43] [44] [45] Interestingly, mobilization of lipids by macroautophagy in the liver is not limited to hepatocytes. For instance, lipophagy is essential for the activation of hepatic stellate As part of its function of controlling quality of cellular components, autophagy eliminates altered proteins and organelles, which otherwise could become toxic. c | Liver autophagy is also activated for defence against hepatic damage resulting from oxidative stress, organelle stress (ER stress depicted here) or that induced by nutrient overload (lipotoxic challenge depicted here). Abbreviations: AA, amino acid; ER, endoplasmic reticulum; FFA, free fatty acid; Glu, glucose.
cells, a key event in liver fibrogenesis, 49 which has led to the idea of transient chemical blockage of autophagy as a possible new therapeutic strategy for liver fibrosis. 49, 50 Autophagy might also contribute to maintenance of the energetic balance in the liver through catabolism of gly cogen, which is another major hepatic energy store. 51, 52 The selectivity of this process, known as glyco phagy, has been reinforced by the discovery that the protein Stbd1 (starchbinding domaincontaining protein 1) serves as the cargorecognizing receptor that delivers glycogen to the autophagosome through interaction with the Atg protein GABARAPL1 (γaminobutyric acid receptor associated proteinlike 1). 53 Microautophagy also par ticipates in delivery and degradation of glycogen in the vacuole in yeast, 54 but it is unknown whether a similar process exists in mammals. More studies are also neces sary to determine whether glycogenolysis, an essential process that provides glucose to extrahepatic tissues, is attributable to any type of autophagy.
Regulation of liver enzyme content
Besides active breakdown of energy stores, autophagy can contribute to the regulation of liver metabolism through the degradation of limiting enzymes in distinct metabolic pathways. CMA seems well suited for this task due to its ability to target single proteins for lysosomal degrada tion. In fact, key glycolytic enzymes have been shown to undergo proteolysis through this selective autophagic pathway. 39, 55 Degradation of regulators of cellular metab olism, such as p62, via macroautophagy has been pro posed to also contribute to the transcriptional control of liver metabolism. 56 In fact, most of the metabolic com promise in the mouse models of defective liver autophagy can be attributed to the accumulation of p62, because loss of autophagy in a p62 null animal presents with a very mild phenotype in comparison. 57 
Mitochondrial turnover
Proper functioning of mitochondria is key for the main tenance of the energetic balance in the liver. These organ elles are most at risk of damage by reactive oxygen species, and often handle this risk by merging with the rest of the mitochondria network and diluting the burden. 58 However, in cases of severe insult, altered mitochon dria are actively excluded from fusing with the network and instead are delivered to lysosomes for complete d egradation through a macroautophagy variant known as mitophagy. 14, [59] [60] [61] Changes at the membrane of the mito chondria are detected by cargorecognizing molecules that bring along the essential components for the formation of the autophagosome. 60, 62 The molecular pair PINK and Parkin, the Bnip3like protein NIX (also known as NIP3 like protein X), p62, and NBR1 (next to BRCA1 gene 1 protein) have all been shown to contribute to mitophagy, although probably in response to different stimuli. 60, 62, 63 For example, PINK and Parkin preferentially facilitate the degradation of depolarized mitochondria, but they are dispensable for s tarvationinduced mitophagy in which Bnip3 has a more prominent role. 63 Mitophagy of damaged mitochondria is initiated through PINK1dependent recruitment to the mitochondria of the ubiquitin ligase Parkin, which targets the protein mito fusin (involved in mitochondrial dynamics) for proteasome degradation. 60 Parkininduced degradation of mitofusin prevents accum ulation of mitochondrial spheroids-the morphological representation of segregated damaged mitochondria often observed in liver injury. 64 Lysosomes might directly fuse with the mitochondrial spheroids as an alternative mech anism for mitochondria degradation when autophagy is compromised. 64 Although mitophagy is an important process in cellular quality control, it also mediates the normal turnover of healthy mitochondria and regulates the size of the mitochondria pool to a ccommodate, for example, changes in nutrient status. 65 
Cellular quality control
Autophagy has an important role in the clearance of abnormal or damaged hepatic proteins and organ elles that would otherwise accumulate and lead to hepato toxicity. Intracellular proteins with abnormal conform ations resulting from faulty synthesis or posttranslational damage are frequent cargo of the different autophagic pathways in the liver. For example, although selective d egradation of oxidized proteins is achieved in part through the proteasome, CMA is also activated in the liver after oxidative injury to mediate the removal of damaged proteins. 32 Blockage of CMA leaves cells more susceptible to oxidative damage, 33 whereas genetic manip ulations that prevent the agedependent decrease of CMA in mouse liver markedly reduce the content of oxidized proteins in this organ. 66 In fact, preservation of normal hepatic CMA activity until late in life in rodents improves overall hepatocyte homeostasis, maintains the ability of the liver to respond to stressors and keeps hepatic func tion in these old animals at levels c omparable to those in young animals. 66 The high levels of oxidative damage detected in the liver in mouse models of compromised autophagy high lights the importance of macroautophagy in the hepato cyte response against oxidative stress. 18 Interestingly, hepatocytes have an antioxidant transcriptional program in place that is activated when autophagy is compromised to ameliorate the subsequent oxidative stress damage. 67 The main regulator of this program, Nrf2, is under the control of an autophagy substrate, p62. Nrf2 is consti tutively trapped by Keap1, which facilitates its degrad ation by the proteasome and maintains its transcriptional activity at a low level. When autophagy fails, p62 accumu lates and its ability to bind Keap1 competitively prevents degrad ation of Nrf2, leading to the activation of the pro tective Nrf2mediated program. [68] [69] [70] However, the effect of Nrf2mediated signalling in the liver might be more complex than initially anticipated because a study has shown that simultaneous elimination of Nrf2, Keap1 and Atg7 in mouse liver reduces the hepatic damage observed in Atg7deficient animals. 71 Although both macroautophagy 72 and CMA 32 become activated during oxidative stress, they are not redundant in their protective functions. In fact, the contribution of one pathway or the other becomes more prevalent depending on the target of the oxidative damage. Conditions with predominantly protein damage benefit from the selec tivity of CMA, whereas organelle injury and accumula tion of protein aggregates are handled for the most part by macroautophagy. Most of the antioxidant effect of macroautophagy has been attributed to its role in the removal of damaged or malfunctioning mitochondria through mitophagy, as described in the previous section ( Figure 3 ). Hepatic autophagy is also important for the maintenance of ER homeostasis. The very high rates of secretory protein synthesis sustained by hepatocytes impose continuous stress in the ER. Cells respond to ER proteotoxicity through the activation of the unfolding protein response (UPR), a local response that upregu lates molecular chaperones, attenuates translation, and enhances degradation of misfolded proteins by the pro teasome. Protein stress inside the ER lumen can also trigger macroautophagy, 73, 74 and this activation is in part mediated by transcription factors such as cJun, 75 but also by some of the factors that participate in the UPR. 76 This coordinated activation of UPR and ER stressinduced autophagy might facilitate the disposal of misfolded pro teins that cannot be fully degraded by the proteasome, as well as facilitate the selective degradation of portions of the ER to expedite recovery of ER homeostasis. 73, 74, 77 The ability of macroautophagy to minimize ER stress has been confirmed in vivo using genetic and dietary mouse models of obesity in which, as described in the following sections, severe compromise of autophagy is responsible for raised ER stress, and restoration of normal levels of autophagy is sufficient to ameliorate this stress. 78 However, consid ering the important contribution of the ER membrane to autophagosome biogenesis, 79 the protective effect of macro autophagy against ER stress could have some limits, as conditions of chronic uncontrolled ER stress might have a negative effect on autophagic function.
In summary, degradation of hepatocyte organelles through autophagy serves both to eliminate those organ elles that malfunction and thus prevent further cellular damage, and also to modulate the size and number of the pool of a particular organelle to adapt to intracellular and extracellular stress. Although the same basic struc tural autophagic components are shared in both cases, the signalling and modulatory pathways might be different depending on the purpose of the autophagic engagement.
Autophagy and liver disease
A growing number of liver pathologies have been asso ciated with primary or secondary autophagic dysfunc tion. In some of these disorders, the consequences of the in adequacy of the autophagic process are closely linked to the role of autophagy in the maintenance of the energetic balance. In other instances, pathology arises because of the inability of hepatic autophagy to eliminate abnormal cellular components or structures damaged as a consequence of the underlying pathology. We have selected examples of liver pathologies in which autophagic malfunction contributes to loss of quality control, metabolic imbalance, or to the inability to carry out a stress response.
α1-antitrypsin deficiency
Failure of both proteasomal degradation and autophagy has been described in the liverspecific protein conform ational disorder known as α1antitrypsin deficiency (Figure 4 ). In this hereditary condition, a point mutation in the plasma protease inhibitor α1antitrypsin, normally synthesized and secreted by the liver, causes trapping of the mutant protein (referred to as ATZ), in the ER in the form of insoluble protein inclusions. 80 This proteo toxic insult ultimately progresses to chronic liver injury, hepatic fibrosis, and on occasion hepatocellular carcin oma (HCC). 81 Proteasomal degradation and autophagy are activated in response to the accumulation of ATZ in the ER and contribute to its degradation. 82, 83 In fact, expression of ATZ in mouse models of α1antitrypsin deficiency is sufficient to activate autophagy in vivo and, conversely, genetic blockage of macroautophagy leads to accumulation of ATZ intracellular inclusions in these animals. 82 Constitutive upregulation of liver macro autophagy in this disease and the subsequent turnover of mutant α1antitrypsin contribute to reduce toxicity, cellular damage and inflammatory responses in hepato cytes. 82 However, liver damage can ultimately occur because the affected hepatocytes cannot further induce autophagy in response to stressors such as starvation, and they also exhibit alterations in mitophagy, which could explain the accumulation of abnormal mitochondria that is characteristic of the disease. 83, 84 Individual variability in the autophagic response of patients might explain the diversity of phenotypic expression and severity of liver disease in α1antitrypsin deficiency and perhaps the predisposition to HCC. 81 The exciting finding that the autophagyenhancing drug carbamazepine is able to decrease the number of ATZcontaining globules and reduce hepatic injury and fibrosis in mouse models of α1antitrypsin def iciency supports the idea that pharmacological upregulation of autophagy might be of therapeutic value 85 ( Figure 4 ). Ongoing pilot studies are currently testing the efficacy of this autophagy activator in patients with α1antitrypsin deficiency and endstage liver failure for which the only current curative treatment is liver transplant ation. 86 The beneficial effect of enhancing autophagy in the α1antitrypsin deficient liver has been further validated in studies with the transcription factor EB (TFEB), a master regulatory gene that controls a tran scriptional program capable of upregulating autophagy and the lysosomal system. 48 Gene transfer of Tfeb rescues the α1antitrypsin deficient phenotype in mice by increas ing the degradation of the oligomeric ATZ protein through autophagy. 87 Although most current efforts are focused on α1antitrypsin deficiency, pharmacologic or genetic activation of autophagy has therapeutic potential for protecting against hepatic damage caused by primary or secondary accumulation of other toxic pathogenic pro teins in the liver. For example, autophagy has been shown to mediate the elimination of hepatic Mallory bodies, 88 which are inclusions of keratin intermediate filaments that form in the liver of patients affected by chronic con ditions such as alcoholic hepatitis, cirrhosis, Wilson's disease and HCC.
Toxic injury to the liver
Autophagy is an essential component of the cellular response to numerous stressors. Of relevance for the liver are the oxidative and hypoxic stress that underlie common types of hepatic injury such as those inflicted by ischaemia-reperfusion or by hepatotoxic drugs, includ ing alcohol. Although autophagy is activated as a protec tive mechanism in most of these instances, compromised autophagic activity, often as a consequence of the effect of the aggressor on autophagy, aggravates the course of disease. Repairing the autophagic defect or enhancing the autophagic capacity of the liver might have curative value in these conditions.
Ischaemia-reperfusion injury
Ischaemia-reperfusion injury, a common complication of liver surgery and transplantation, is a result of the insult to hepatocytes during the ischaemic period and the sub sequent damage from the activation of proinflammatory pathways and elevation of oxidative stress. Initial studies reported contradictory data on the protective or damag ing effect of autophagy during i schaemia-reperfusion injury. Part of the confusion originates from the fact that readouts of the autophagic process in studies with animal models in vivo and in patients are often limited to electron microscopy analysis or measurement of Atg proteins levels, which provide information on the steady state of autophagy but lack functional measurements. For example, an increase in the number of autophagosomes observed by electron microscopy or in the levels of integ ral autophagosome Atg proteins could be a result of enhanced induction of autophagy but could also be the result of compromised clearance of autophagosomes.
Thus, general agreement exists that multiple factors have to be taken into consideration in the interplay of autophagy with ischaemia-reperfusion injury.
The effect of autophagy blockage or upregulation in ischaemia-reperfusion injury can be influenced by the ischaemic time, temperature, method of organ pres ervation, previous liver conditions and even ageing. In the case of liver surgery, a single ischaemic event does not seem sufficient to induce autophagy, but ischaemic precon ditioning (brief periods of vascular occlusion shown to be protective against ischaemia-reperfusion injury) enhances autophagic upregulation and decreases necrosis. 89 Autophagy involvement is different in the case of transplants owing to the low temperature utilized to preserve the donor's liver. The switch from cold to warm temperature during reperfusion is associated with an increase in autophagic vacuoles in the transplanted liver, 90 which could be in part triggered by the lack of nutrients in the preserving solution. 91 Claims of the deleterious effect of autophagy under these conditions are based on the hepatic protection observed upon treatment with phospho inositide (PI) 3kinase inhibitors or inhibitors of lyso somal proteo lysis. 92 However, these compounds have effects beyond autophagy, and in the case of lysosomal proteolysis inhib itors, a study with chloroquine found that although bene ficial in the early period, it aggravates liver damage in later i schaemia-reperfusio n stages. 93 The idea of a beneficial effect of autophagy in liver transplantation is gaining more support because upregu lation of autophagy is a common feature of interventions shown to be protective against ischaemia-reperfusion injury such as pretreatment with proteasome inhibitors, 94 AMPK 95 and CaMKIV (calcium/calmodulindependent protein kinase IV) 96 activators or lithium. 97 In addition, general consensus exists that upregulation of autophagy has a beneficial effect in cases in which autophagy in the donor liver is reduced to start with, for example, in stea totic rodent and human liver grafts, 95, 98 and in experi mental animal models when using livers from old mouse donors, 99 or mouse livers subjected to pretreatments, such as hydrogen sulphide, that reduce autophagic activity. 100 Although further investigation is required to under stand the basis for autophagic protection against hepatic ischaemia-reperfusion injury, the ability of autophagy to contribute amino acids, to remove the damage caused by anoxia and to reduce generation of reactive oxygen species by elimination of mitochondria by mitophagy 101 are all likely mechanisms.
Alcohol abuse
Owing to the role of the liver in xenobiotic metab olism, hepatocytes are exposed to many chemicals that at high toxic concentrations often interfere with hepatic lysosomal protein degradation. 102 For example, the liver is the organ that sustains the highest level of damage during alcohol abuse. Hepatocytes have been show to u pregulate autophagy in response to alcohol exposure. 103 The autophagic increase is selective for lipophagy and mitophagy, which interestingly target the two organelles most affected by the alcohol intoxication exposure, that is, lipid droplets and mitochondria. 103 However, reduced autophagic activity upon exposure to alcohol has also been reported in other studies, 104, 105 which suggests that different factors, such as the duration of the alcoholic intoxication, might modulate the effect on autophagy. For example, although autophagic activation might occur in response to the oxidative stress resulting from alcohol catabolism in hepatocytes, 106 primary and secondary oxi dants generated during this process have been described to upregulate autophagosome synthesis but prevent their clearance because of their toxic effect on lysosomes. 107 The inhibitory effect of alcohol on autophagy can also be secondary to the inhibition of AMPK after chronic ethanol consumption 108 or to the increase in hepatic lipids that occurs as result of SREBPinduced lipogenesis. 109 Considering these inhibitory effects of longterm alcohol consumption on autophagy, chemical upregulation of this pathway might be of use against alcoholinduced liver damage.
Paracetamol overdose
Hepatic toxicity caused by overdoses with paracetamol is another clinically relevant condition in which the therapeutic value of modulating autophagy has been explored. Treatment with rapamycin has been shown to reduce the liver injury caused by this drug, suggesting a protective role for autophagy. 44 The severe damage that paracetamol's reactive metabolites cause in mitochon dria is probably the trigger for the observed activation of Parkindependent mitophagy. 64, 110 NAFLD and the metabolic syndrome Multiple levels of interaction have been described between liver autophagic function and NAFLD. The characteristic accumulation of hepatic lipids in this condition is often a consequence of increased lipid influx in this organ, enhanced de novo synthesis of hepatic lipids and reduced mobilization and utilization of liver lipid stores. 111 The high prevalence of NAFLD in individ uals with type 2 diabetes or with morbid obesity suggests common patho genic mechanisms for all these conditions. The fact that alterations in autophagy have been described in NAFLD, obesity and diabetes has led to proposals that autophagic failure might underlie the metabolic syndrome and justi fies the current interest in exploring the use of chemical m odulators of autophagy in its treatment. [111] [112] [113] As in other diseases, the interplay between NAFLD and autophagy might change as the disease progresses, and the failure of autophagy might be a cause or a consequence of the disease ( Figure 5 ). The role of macroautophagy in the mobilization of hepatic lipids 43 supports a pro tective role of autophagy against NAFLD and explains why hepatocytes upregulate autophagy in response to dietary lipid challenges as a mechanism of defence against lipo toxicity. 43, 113 In fact, studies in mouse models overexpressing Tfeb have demonstrated that this factor protects against steatosis induced by a highfat diet in an autophagydependent manner. [46] [47] [48] In addition to the protective effect of lipid mobilization by lipophagy, autophagy might also be beneficial against the ER stress associated with lipotoxicity. However, the defensive effect of autophagy in this condition might have limitations as studies have attributed hepatic steatosis and compro mised turnover of lipids in models of NAFLD, at least partially, to a reduction of autophagic activity. 78, 114 Failure of autophagy in NAFLD might be explained by obser vations that chronic exposure to a highfat diet or acute exposure to a cholesterolenriched diet actually inhibits autophagy. 43, 113 Upregulation or inhibition of autophagy in response to a lipid challenge might be dependent not only on the intensity and duration of the challenge but also on the types of lipids. For example, hepatocyte expo sure to unsaturated fatty acid induces autophagy whereas exposure to saturated fatty acids suppresses autophagy and induces apoptosis. 45 However, the compromise of autophagy in hepatosteatosis might still be reversible, because injection of TFEB in mice being fed a highfat diet stops the development of obesity in an autophagy dependent manner. 48 Furthermore, the same intervention in a genetic mouse model of obesity improves the meta bolic syndrome phenotype, 48 which suggests that activa tion of autophagy under these conditions might not only have preventive value but also could be utilized in the treatment of the metabolic syndrome, at least in the case of autophagy induced by TFEB.
Several mechanisms might be responsible for the autophagic failure in NAFLD. Lipidenriched diets have been shown to impose changes in the membrane lipid composition of autophagosomes and lysosomes that reduce their fusogenic capacity, thus inhibiting completion of the autophagic process. 113 These dietinduced changes in the lysosomal membrane also have a negative effect on CMA, as they reduce the stability of the CMA receptor in lysosomes. 114 Interestingly, changes in the lipid com position of the lysosomal membrane upon dietary chal lenges are remarkably similar to those observed during physiological ageing, a condition also associated with reduced CMA, 115 which underscores the importance of environmental influences and nutritional choices on liver autophagic function. Impairment of autophagy in NAFLD might also occur at the level of induction owing to changes in cellular signalling. Autophagy in the liver is normally suppressed by insulin signalling, 9 which suggests that conditions with insulin resistance, such as NAFLD and obesity, should lead to augmented hepatic autophagy. However, experimental evidence has revealed suppres sion of liver autophagy and mitophagy in mouse models of obesity with insulin resistance and hyper insulinaemia through a FoxO1dependent mechanism. 114 Reduced autophagy under these conditions is in part a consequence of decreased expression of essential Atgs, which interest ingly occurs whether the hyperinsulinaemia is norm alized or not. 78, 114 Surprisingly, restoration of normal hepatic autophagic function in the context of obesity is sufficient to improve hepatic insulin action and restore peripheral glucose tolerance. 78 This unexpected turn of events, by which autophagy modulates sensitivity to its own inhib itor, insulin, seems to originate from the ability of this pathway to attenuate ER stress, which has been proven to contribute to insulin insensitivity. 78 When considering the course of NAFLD, it is still a matter of debate whether the compromised autophagic function in the liver is a consequence of obesity and changes in insulin sensing or whether hepatic autophagy impairment strikes earlier on in the metabolic syndrome, and is followed by hepatic steatosis, lipotoxicity and meta bolic dysregulation. Examples of both scenarios have been documented. [43] [44] [45] 114, 116 As described before, the secondary compromise of autophagy by dietary lipids is now well supported, 43, 113, 116 but it is plausible that the primary defect in autophagic function associated with age could be the trigger for inadequate lipid handling in the liver and the subsequent metabolic dysfunction (for example, in the case of the metabolic syndrome associated with ageing). Distinguishing between cause and consequence might not always be possible, but the identification of this bidirec tional interplay between autophagy and lipids in the liver supports the notion that breaking this vicious cycle, either by enhancing autophagy function or reducing the inhib itory effect of the metabolic imbalance (lipids and insulin) on this pathway, should help in these situations.
The possible therapeutic value of modulating autophagy in these abnormal metabolic conditions has not been clinically tested yet but drugs such as carbamaz epine and rapamycin have shown promising effects in the reduction of liver steatosis induced in rodents by either dietary lipids or alcohol ( Figure 5) . 117 Whether the therapeutic benefit is in part or fully attributable to their stimulatory effect on autophagy requires future investiga tion. Furthermore, the improvement of the metabolic con ditions in mouse models of dietinduced obesity subjected to caloric restriction or exercise has been correlated with the positive effect of both interventions on autophagy. 112 
Viral infections
Autophagy aids in the removal of pathogens (a process called xenophagy) by working in conjunction with the innate immune system. However, several micro organisms have evolved unique mechanisms to circumvent, sup press, or exploit autophagic machinery to ensure their own survival and replication ( Figure 6 ). [118] [119] [120] For instance, herpes simplex virus1 and HIV1 block autophagy to abrogate their degradation through this pathway by blunting autophagosome formation or interrupting a utophagosome-lysosome fusion, respectively. 121, 122 By contrast, pathogens such as polio and dengue activate autophagy to enhance their own replication. 123 
HBV infection
In the case of the liver, considerable attention has been paid to the interplay between autophagic degradation and viral hepatitis. HBV-a hepatotropic DNA virus associ ated with acute viral hepatitis and chronic liver diseases such as cirrhosis and HCC 124 -induces autophagy in cells in culture, transgenic mice and in livers from infected patients. [125] [126] [127] Paradoxically, despite the increased number of autophagosomes produced, protein breakdown is not augmented, suggesting that HBV induces the early autophagy stages but halts autophagosome matur ation and clearance. 125, 126 HBVmediated induction of autophagy has been attributed so far to the action of two different viral proteins, the HBV X protein (HBx) and the small surface protein. 125, 126, 128 The multifunctional regula tory protein HBx has been shown to activate the kinase activity of the autophagy initiation complex 125 and also to induce the expression of Beclin1, the most important modulator of that complex. 128 In the case of the small surface protein, activation of autophagy might be sec ondary to its ability to induce ER stress. 126 How precisely autophagy contributes to enhancing HBV viral replication is still unclear, but most studies support an effect on DNA replication and viral envelopment. 125, 126 The inability of HBV to replicate in vivo in mouse models with compro mised macroautophagy has provided rationale for the claim that pharmacological inhibition of autophagy might be a reasonable adjuvant therapeutic strategy to treat patients infected with HBV. 127 
HCV infection
Autophagic changes have also been observed in mouse livers and human hepatocytes in culture upon infection by the RNA virus HCV, which shares with HBV its hepato tropism and ability to cause acute hepatitis and chronic liver disease. 129 Independent of HCV genotype, a consist ent increase in the number of autophagosomes is observed in HCVinfected hepatocytes. [130] [131] [132] Although reports are conflicting about whether fusion of autophagosomes with lysosomes is required or not for the beneficial effects of autophagy on viral RNA replication, consensus exists on the capability of HCV to drive autophagic activation. Several HCV nonstructural proteins interact with Atg proteins and can directly induce autophagosome form ation. 133, 134 Interestingly, besides upregulation of core com ponents of the autophagy machinery, HCV infection also induces expression of selective autophagy effectors such as PINK1 and Parkin to specifically drive mitophagy. 135 As with HBV, some HCV proteins can induce autophagy in infected cells through activation of the UPR in the ER. 132, 136, 137 In fact, suppression of the ER stress signals in this context diminishes HCV replication, demonstrating that the induction of autophagy caused by HCV depends on an intact ER stress response. 132, 136 The precise mechanism of how autophagy promotes HCV replication remains elusive, but several studies have suggested that autophagic vacuoles might act as a membra nous web-a complex of viral proteins, replicating RNA and altered cell membranes-that serves as a transient scaffold for efficient translation of viral RNA ( Figure 6 ). 138 Autophagosomes might also facilitate viral replication by sequestering negative regulators or conversely by attract ing viral proteins needed for virion propagation. 131, 139 For example, proviral autophagy proteins Atg5, Atg12 and Beclin1 are required for delivery of incoming viral RNA to the translation apparatus for initi ation of HCV replication. 131 Similarly, Atg5 has been shown to interact with HCV NS5B, a viral protein necessary to establish the membranebound replication complex that catalyzes RNA synthesis. 139 Interestingly, this interaction is transient, emphasizing the importance of autophagic involvement during the onset of viral infection but not necessarily to sustain it. 131, 139 Lastly, part of the beneficial effect of block age of autophagosome clearance in viral replication might be accomplished by preventing degradation of lipid drop lets, which are known to be a favourite site for assembly and production of HCV virions. 140 Blockade of liver autophagy could become a therapeutic option for treatment of HCV infection, as silencing of dif ferent autophagy proteins has been shown experimentally to be effective in inhibiting viral replication, decreasing intracellular HCV levels and extracellular infectivity. 131, 139 Furthermore, suppression of autophagy in infected cells induces severe cytoplasmic vacuolation and cell death, underscoring the importance of autophagy in minimiz ing toxic vacuole formation. 137 Part of the beneficial effect of suppression of macroautophagy in the context of HCV infection might be attributable to enhancement of the host's innate immune system ( Figure 6) . 136, 141 Inhibition of autophagy in HCVinfected hepatocytes activates inter feron signalling and induces apoptosis. 136, 141 Overall, given that autophagy seems to be important in the early stages of infection, autophagy blockers might be bestsuited for immediate treatment upon HCV exposure.
Hepatocellular carcinoma
Early studies of macroautophagy in cancer emphasized its tumoursuppressive function on the basis that autophagy was reduced in different types of liver cancer 142 and that in normal cells autophagy helps mitigate damage during genotoxic and proteotoxic stress, assuring chro mosomal stability and reducing chances of malignant transform ation 143, 144 (and reviewed elsewhere [145] [146] [147] [148] ). The fact that several tumour suppressor proteins induce macro autophagy whereas some oncogenic proteins inhibit this process also reinforced the antioncogenic role of autophagy. 146, 148 In the case of the liver, the idea that reduced levels of autophagy will favour cell prolifer ation fit well with the early findings that autophagy and overall protein catabolism were inhibited in the regener ating liver following partial hepatectomy to promote the switch from a catabolic to an anabolic state. 149 However, later studies have revealed that the role of autophagy in tumori genesis is contextdependent (Figure 7) . Some cancer cells can upregulate autophagic activity to enhance their survival in the hostile tumour microenvironment, thus promoting tumour growth. [146] [147] [148] This protumori genic effect occurs in part because macroautophagy efficiently removes the deleterious products caused by endogenous damage (hypoxiainduced reactive oxygen species) or exogenous damage (cytostatic or cytotoxic drugs), 150 and in part because autophagy assists these cells to main tain a positive energetic balance in the face of increasing metabolic demands. 56, 151 In the case of HCC, the most prevalent form of liver cancer, most studies support a tumoursuppressive func tion of autophagy. HCC cell lines and tumour biopsy samples often exhibit decreased expression of autophagy markers. 152 In fact, there is an inverse correlation between the aggressiveness of the HCC and autophagic activity that links diminished autophagy with poorer prognosis. 152 Likewise, expression of Atgs such as Beclin1 after cura tive resection has been shown to correlate with disease free survival in patients. 152 Experimental evidence also supports the protective effect of liver autophagy against carcinogenesis, as mice with heterozygous disruption of Beclin1 are prone to developing spontaneous malignan cies, including HCC and accelerated HBVinduced carcin omas. 153 Other studies have demonstrated that autophagy exerts a procarcinogenic effect in HCC by protecting hepatic cancer cells from damage resulting, for example, from hypoxic stress, 150, 154 or by inducing expression of factors that stimulate cell invasion and metastasis. 155 The precise mechanisms that lead to autophagic alterations in HCC have yet to be uncovered, as are the conditions and/or the timings that determine whether and when tumour cells upregulate or downregulate macroautophagy.
However, the fact that some tumour suppressors and oncogenes directly modulate autophagy and that several signalling pathways regulating autophagy closely overlap with those that regulate tumorigenesis (reviewed else where 145, 146, 156 ) supports the existence of continuous feed back between both processes. For example, the signalling adaptor p62 has risen as one of the favourite candidates in the regulation of the interplay between carcinogenesis and autophagy in light of the previously mentioned effect of p62 on the activation of the Nrf2dependent transcrip tional program. 68, 157 Increase in p62 levels and induction of Nrf2 have been described in >25% of human HCC biopsy samples, and experimental blockage of p62 in HCC cell lines is effective at reducing cell growth. 157 The potential of chemical modulation of macroauto phagy as antioncogenic therapy is undergoing testing in clinical trials for several types of cancers. One of the requirements before pharmacologically manipulating autophagy in HCC is to gain a clear understanding of whether autophagy is depressed or upregulated at the time of the intervention. In addition, current antiHCC treatments have different effects on macroautophagy, which might determine the selection of inhibitors or activators of this pathway as coadjuvant therapeutics. For example, sorafenib, common in the treatment of advanced HCC, showed improved efficacy in causing cell death in vitro and in vivo when used in combination with pharmacological inhibitors of autophagy. 158 In fact, induction of autophagy by this drug has been proposed to contribute to the acquired drug resistance in patients with HCC. 159 Inhibition of autophagy also increases the effi cacy of antiangiogenic agents against HCC. 160 However, blockage of autophagy might not be a universal approach as a coadjuvant agent in HCC therapy given that other drugs, such as histone deacetylase inhibitors, actually stimulate autophagy and depend on its a ctivation to cause cytotoxicity and death in cancer cells. 161 Other current limitations to the generalized use of macro autophagy modulators in HCC therapeu tics is the rather limited number of available com pounds. Rapamycin and other derivatives acting on the mTOR complex, the most commonly used activators of autophagy, have shown antitumour efficacy in advanced HCC in a phase II study, 162 but their additional autophagy independent effects on processes such as protein trans lation and cellular growth highlights the need for more potent and selective autophagy activators. Similar limita tions apply to chloroquine, an agent that disrupts lyso somal acidification and that is the leading compound used in the clinic to block autophagic flux. An emerging altern ative to chemical modulation of autophagy in the treat ment of HCC could be gene therapy to target microRNAs described to u pregulate or downregulate autophagy. 163 A role for CMA in cancer cell metabolism has also been identified, in this case by contributing to maintaining high rates of glycolysis in transformed cells. 164 CMA activity has been shown to be constitutively active in different types of cancer, including HCC, regardless of the status of macro autophagy. 164, 165 The fact that genetic inhibition of CMA in human cancer cell lines or in tumours of human cancer cells in mice effectively reduces tumour growth and meta stasis 164 supports the possible antioncogenic therapeutic value of negative modulators of this pathway.
Conclusions
The relevance of autophagy in liver physiology goes beyond the initially reported role as a supplier of amino acids during starvation. New roles for autophagy encom pass a complex array of functions, including global regula tory effects on liver metabolism, essential roles in protein and organelle quality control, and active defence against liver pathogens. The complexity of hepatic autophagy stems not only from its diverse roles in physiologic and pathophysiologic processes but also from the multiple mechanisms that contribute to its regulation.
Despite the general agreement on the beneficial effects of autophagy activation in liver physiology and in the protection against liver diseases, manipulation of this pathway with therapeutic purposes might not be as clear cut as anticipated. In almost every liver pathology, block age of autophagy can have opposite effects depending on differences in the type, duration and intensity of the pathogenic insult and on the way in which hepatocytes react to this insult. When autophagy manipulation is considered as adjuvant to other therapeutic approaches, the effect of these other interventions on the autophagic pathway might also dictate the choice of activators or inhibitors of autophagy. The array of compounds avail able to modulate autophagy is still fairly limited and most of them target the same autophagy steps (frequently ini tiation), whereas trafficking, fusion and degradation are still poor drugable targets. The development of disease specific autophagy modulators requires a more complete understanding of the different signalling pathways that converge on autophagy and how they differentially regu late basal versus inducible or selective versus non selective autophagy. In fact, although blockage of autophagy has been shown to be effective in reducing liver damage in different diseases, complete longterm inhibition of autophagy would eventually have a detrimental effect on this organ, and consequently drugs that target only induc ible autophagy but preserve constitutive autophagy would be desirable in those chronic settings. Such drugs would enable us to better target the specific autophagy pathway altered in the disease of interest without p erturbing the global autophagic process in hepatocytes.
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